BLRX Bioline Rx Ltd

  1. Stocks
  2. Healthcare
  3. NASDAQ: BLRX

Price (delayed)

$2.49

Market cap

$13.05M

P/E Ratio

N/A

Dividend/share

N/A

EPS

$0

Enterprise value

$7.92M

?
Relative Growth: Rel. Growth: 0
Relative Strength: Rel. Strength: 21
Relative Valuation: Rel. Valuation: 9
Relative Profitability: Rel. Profitability: 20

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates ...

Highlights
The debt has declined by 37% year-on-year and by 12% since the previous quarter
Bioline Rx's gross margin has increased by 35% YoY
The revenue has plunged by 92% YoY
The company's gross profit has shrunk by 89% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.biolinerx.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of BLRX

BLRX stock price

How has the Bioline Rx stock price performed over time
Intraday
2.47%
1 week
0.4%
1 month
-11.39%
1 year
-33.42%
YTD
-10.11%
QTD
-20.19%

Financial performance

How have Bioline Rx's revenue and profit performed over time
Revenue
$1.39M
Gross profit
$1.11M
Operating income
-$12.17M
Net income
-$9.29M
Gross margin
80%
Net margin
-667.3%
The revenue has plunged by 92% YoY
The company's gross profit has shrunk by 89% YoY
Bioline Rx's gross margin has increased by 35% YoY
BLRX's net income is down by 19% YoY and by 4.5% QoQ

Price vs fundamentals

How does BLRX's price correlate with its fundamentals

Growth

What is Bioline Rx's growth rate over time

Valuation

What is Bioline Rx stock price valuation
P/E
N/A
P/B
0.94
P/S
9.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
5.69
The stock's price to book (P/B) is 68% less than its 5-year quarterly average of 2.9 but 2.2% more than its last 4 quarters average of 0.9
The equity has contracted by 31% YoY and by 17% from the previous quarter
The revenue has plunged by 92% YoY
BLRX's P/S is 9% above its last 4 quarters average of 8.5

Efficiency

How efficient is Bioline Rx business performance
Bioline Rx's ROIC has plunged by 155% from the previous quarter
BLRX's return on assets is down by 39% year-on-year and by 11% since the previous quarter
Bioline Rx's return on equity has decreased by 14% QoQ and by 10% YoY
BLRX's return on sales is down by 7% since the previous quarter

Dividends

What is BLRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BLRX.

Financial health

How did Bioline Rx financials performed over time
The company's total assets is 99% higher than its total liabilities
Bioline Rx's quick ratio has decreased by 45% YoY and by 28% QoQ
The company's current ratio fell by 42% YoY and by 24% QoQ
The debt is 42% smaller than the equity
The debt has declined by 37% year-on-year and by 12% since the previous quarter
The equity has contracted by 31% YoY and by 17% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.